DBIA
FLNA

Dumont & Blake Investment Advisors’s Filana Therapeutics FLNA Stock Holding History

Dumont & Blake Investment Advisors’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-6,000
Closed -$262K – 225
2021
Q4 		$262K Buy
+6,000
New +$315K 0.07% 177

Other funds holding FLNA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Dumont & Blake Investment Advisors's FLNA Position: Q1 2022 in Review

Dumont & Blake Investment Advisors sold out of Filana Therapeutics (FLNA) in Q1 2022, closing a stake of 6,000 shares — an estimated $262K sold.

Dumont & Blake Investment Advisors first reported a position in FLNA in Q4 2021 and held it in 1 quarter. The position peaked at $262K in Q4 2021. 163 funds tracked by Wall St. Rank hold FLNA as of Q1 2022.

  • Dumont & Blake Investment Advisors reported no remaining Filana Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Dumont & Blake Investment Advisors sold 6,000 Filana Therapeutics shares in Q1 2022, an estimated $262K.
  • Dumont & Blake Investment Advisors first reported a position in Filana Therapeutics in Q4 2021 and held it in 1 quarter.
  • Dumont & Blake Investment Advisors's Filana Therapeutics position peaked at $262K in Q4 2021.
  • 163 funds tracked by Wall St. Rank held Filana Therapeutics as of Q1 2022.

Based on Dumont & Blake Investment Advisors's 13F filing for Q1 2022, filed 27 Apr 2022.